Yahoo

Edwards solidifies TAVR dominance in long-term trial readout

Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, as global demand for the technology increases. The company ...
Business Wire

Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...
Business Wire

Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025

SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
Healio

TAVR for asymptomatic severe aortic stenosis superior to surveillance regardless of age

Please provide your email address to receive an email when new articles are posted on . The benefit of TAVR vs. clinical surveillance for patients with asymptomatic severe aortic stenosis did not vary ...
BioWorld

Edwards: TAVR wavers, mitral valve shines

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...